EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
The pooled prevalence of GERD in the Indian population is 15.6 %
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Subscribe To Our Newsletter & Stay Updated